| Sep 16 |
Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia
|
| Sep 3 |
Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11
|
| Aug 26 |
REPEAT -- Diamond Equity Research Releases Update Note on Altamira Therapeutics Ltd. (NASDAQ: CYTO)
|
| Aug 23 |
Altamira Therapeutics extends distribution agreement with Pharma Nordic
|
| Aug 23 |
Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark
|
| Aug 22 |
Altamira Therapeutics files mixed shelf offering
|
| Aug 16 |
Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances
|
| Aug 12 |
Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models
|
| Jul 19 |
Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles
|
| Jun 20 |
Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management
|
